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The last decade has witnessed a revival of
interest by some in hormesis, a biological phe-
nomenon broadly deﬁned as a “stimulatory”
response to low doses of a substance that oth-
erwise causes inhibition of response at higher
doses (e.g., Calabrese and Baldwin 2002a). 
Hormesis is a type of dose–response
relationship, of which two general forms
exist. Monotonic dose–response (MDR) rela-
tionships describe responses that proceed
unidirectionally from zero dose or doses
above zero. Nonmonotonic dose–response
(NMDR) relationships show biphasic or bidi-
rectional responses to dose, appearing in
U-shaped or inverse U-shaped graphic forms.
Graphic depictions of these responses appear
in a number of articles (e.g., Calabrese and
Baldwin 2001a, 2001b, 2001c; Davis and
Svendsgaard 1994). 
Hormesis in its current form has had
surprisingly little systematic scientiﬁc scrutiny
or collective peer review. Thayer et al. (2005)
evaluated the relative merits and limits of
hormesis as the “default assumption” for
human health risk methodologies and associ-
ated policies. They identiﬁed lack of a mecha-
nistic footing, questionable interpretations of
hormetic data, and underestimation by pro-
ponents of the complexity and diversity of
human population response to xenobiotic
exposures.
The specific scientific framing questions
for hormesis in this analysis are as follows: 
•What is a coherent and valid working
deﬁnition for hormesis? 
• What is its generalizability? 
• What is the evidence for or against hormetic
phenomena in humans? 
• Has any general underlying mechanism
been adequately documented? 
• What are limits to borrowed mechanisms? 
• Can typical single end point hormesis
accommodate multiple toxic end points,
target organs, and toxicologic mechanisms? 
• Is hormesis a valid default assumption in
human risk assessment and exposure reduc-
tion policies?
Deﬁning Hormesis 
Hormesis has been plagued by absence of a
stable deﬁnition. First, development of a deﬁ-
nition has been an ad hoc process, with back-
ing and ﬁlling over time. This ad hoc process
has not been shaped by hypothesis testing but
by the persistent search for, and analysis of,
existing bodies of data [see Calabrese and
Baldwin (2002a) for a current deﬁnition and
its changes over time].
Definitions of hormesis also arose with
little disciplinary consensus in relevant ﬁelds
from expert committees using objective,
arms-length approaches and guidelines. 
Calabrese and Baldwin (2002a) define
hormesis comprehensively as 
an adaptive response characterized by biphasic
dose responses of generally similar quantitative
features with respect to amplitude and range of
the stimulatory response that are either directly
induced (i.e., direct stimulation hormesis [DSH])
or the result of compensatory biological processes
following an initial disruption in homeostasis
(i.e., overcompensation stimulation hormesis
[OCSH]).
There are still differences of opinion on this
deﬁnition. It is largely driven by speculation
and difficult to test empirically at present
(Kitchin 2002; Pickrell and Oehme 2002).
Others question the appropriateness of the
term “hormesis” to cover all low-dose responses
(Chapman 2002). “Direct” stimulation, one-
half the deﬁnition, is descriptive only and lacks
a mechanism. Overcompensation stimulation
linked to preservation of homeostasis is offered
as the mechanism of hormetic action.
Proponents of hormesis often attach the
notion of “beneﬁt” to hormesis. If an adverse
effect has the dose–response curve going one
way, then the opposite direction is deemed
beneficial. This is argument by anomaly
rather than by empirical evidence. The
Calabrese and Baldwin (2002a) definition
uncouples “benefit” from hormesis, given
that hormesis is not inherently “beneficial”
and can be deleterious to health. Anticancer
drug actions that inhibit tumorigenesis in the
normal dose–response range may be preceded
by tumor cell proliferation, that is, an adverse
end point, at low doses (Calabrese 2005a).
Some still believe that hormetic responses are
typically beneficial (Calabrese 2005b; Eaton
and Klaassen 2003). 
What Is Its Generalizability?
Various articles by Calabrese and Calabrese
and Baldwin [see Calabrese (2005b) for cita-
tions] traced the early history of what is known
as hormesis and claim it was “marginalized”
unfairly. These authors assert that early 20th
century research established hormesis suffi-
ciently to warrant scientiﬁc acceptance but for
unfavorable biases from influential scientists
and linkage to homeopathy. Other claimed
impediments are the evolution of risk assess-
ment models favoring the high-dose realm of
dose responses and public pressures for dealing
with high-dose not low-dose exposures. 
Review of the cited studies yields little
convincing evidence that a strong earlier bias
existed. More prosaic reasons likely applied.
First, it would be reasonable to expect that
experimental anomalies would garner less
Address correspondence to P. Mushak, PB Associates,
714 9th St., Ste. 204, Durham, NC 27705-4849
USA. Telephone: (919) 286-7193. Fax: (919) 286-
7369. E-mail: pandbmushak@cs.com 
I thank J.M. Davis for a number of discussions
and B. Mushak for editing assistance.
The author declares he has no competing ﬁnancial
interests.
Received 16 August 2006; accepted 4 January 2007.
Hormesis and Its Place in Nonmonotonic Dose–Response Relationships:
Some Scientiﬁc Reality Checks 
Paul Mushak
PB Associates, Durham, North Carolina, USA
OBJECTIVE: This analysis is a critical assessment of current hormesis literature. I discuss deﬁnitions,
characterization, generalizability, mechanisms, absence of empirical data specific for hormesis
hypothesis testing, and arguments that hormesis be the “default assumption” in risk assessment. 
DATA SOURCES: Hormesis, a biological phenomenon typically described as low-dose stimulation
from substances producing higher-dose inhibition, has recently garnered interest in several quarters.
The principal sources of published materials for this analysis are the writings of certain proponents
of hormesis. Surprisingly few systematic critiques of current hormesis literature exist. Limits to the
phenomenon’s appropriate role in risk assessment and health policy have been published.
DATA SYNTHESIS: Serious gaps in scientiﬁc understanding remain: a stable deﬁnition; generalizability,
especially for humans; a clear mechanistic basis; limitations in the presence of multiple toxic end
points, target organs, and mechanisms. Absence of both arms-length, consensus-driven, scientiﬁc eval-
uations and empirical data from studies speciﬁcally designed for hormesis testing have limited its
acceptance. 
CONCLUSIONS: Deﬁnition, characterization, occurrence, and mechanistic rationale for hormesis will
remain speculative, absent rigorous studies done specifically for hormesis testing. Any role for
hormesis in current risk assessment and regulatory policies for toxics remains to be determined. 
KEY WORDS: bidirectional dose response, biphasic dose response, hormesis, nonmonotonic dose
response. Environ Health Perspect 115:500–506 (2007). doi:10.1289/ehp.9619 available via
http://dx.doi.org/ [Online 4 January 2007]attention than the research’s major focus.
Second, such anomalies would not be easily
interpretable, given the stage of science at the
time. Third, risk assessment itself and risk
assessment models using dose–response data
are of recent vintage and chronologically
unconnected with any early scientiﬁc views of
hormesis. Risk assessment approaches largely
trace to the 1983 seminal monograph
Risk Assessment in the Federal Government:
Managing the Process by the National
Academy of Sciences/National Research
Council (NAS/NRC 1983). The beginnings
of U.S. regulatory agency uses of risk assess-
ment are traced there mainly to the late
1970s. The U.S. Environmental Protection
Agency (EPA) computerized database of
dose–response information, the Integrated
Risk Information System (IRIS; U.S. EPA
2007), did not see routine online use until the
early 1990s. 
The current period of published interest in
hormesis dates to about 1992, but a still prob-
lematic definition did not appear until
10 years later (Calabrese and Baldwin 2002a).
This lag helps quell arguments that slow or lit-
tle acceptance of earlier incarnations of horme-
sis was scientiﬁc hostility and not simply the
workings of science.
The current reception accorded hormesis
by the scientiﬁc and health communities has
been mixed. Cook and Calabrese (2006)
overstate acceptance and understate wide
skepticism. Considerable skepticism about the
nature and scope of hormesis in humans
exists (see below) and is science based.
Characterization and application of hormesis
sufﬁcient for scientiﬁc acceptance are hobbled
by flaws in existing data and the paucity of
statistically and empirically well-designed
studies for hormesis hypothesis testing. 
Definition of a phenomenon is not the
same as its identiﬁcation and characterization.
Attempted identiﬁcation and characterization
of hormesis are occurring simultaneously with
developing a definition. Investigators must
develop criteria for recognition, characteriza-
tion, and generalizability. They especially
must establish that it is biologically and toxi-
cologically signiﬁcant, and not merely a gross
biodynamic or biokinetic artifact that is rela-
tively invariant in magnitude or range across
systems and substances. 
It is clear something is occurring at low
dose in some dose–response relationships
anomalous to the rest of the curve (e.g.,
Calabrese and Baldwin 2001a, 2001c, 2002a).
Criteria for presence or absence of hormetic
responses in published studies, like its other
elements, lack consensus from the scientific
community. Two critical questions are
whether both “numerator” and “denomina-
tor” for establishing hormesis frequency in
nature can be reliably captured by published
literature and whether examined literature
captures published literature. 
What is the minimal frequency for the
occurrence to be termed “generalizable?”
Proponents use ambiguous measures for gen-
eralizability, including “widely and indepen-
dently observed” (Calabrese and Baldwin
2001c), “frequently encountered” (Calabrese
and Baldwin 2001b), and “ubiquitous” (Cook
and Calabrese 2006). These terms for horme-
sis in its current state conﬂict with usual dic-
tionary deﬁnitions for “generalizability.” For
example, “ubiquitous” means “existing or
being everywhere at the same time” (Merriam-
Webster Inc. 2002).
Davis and Svendsgaard (1994) examined
a preselected database to determine the fre-
quency of hormetic responses sufficient to
clearly show U-shaped or inverse U-shaped
curves. They used peer-reviewed literature in
the U.S. EPA’s IRIS database for toxicants,
focusing on information for determining a
reference dose (RfD). The RfD is the daily
lifetime intake of a substance not likely to be
harmful. They found that about one-sixth
(17%) of toxicology articles met their selec-
tion criteria, the fraction giving some indica-
tion of nonmonotonic relationships was 22%,
and 93 or 12% of 780 showed an adequate
U-shape or inverse U-shape dose–response
relationship. They concluded that such
responses are roughly 12–24% of published
dose responses using their methodology. 
Calabrese and co-workers also evaluated
the generalizability of the hormetic response
in published literature (Calabrese and
Baldwin 1997, 2001a; Calabrese and Blain
2005; Calabrese et al. 1999). Their gathered
database provided about 20,000 articles from
selected journals using ad hoc criteria
(Calabrese and Baldwin 1997). A point sys-
tem was developed (Calabrese and Baldwin
2001a; Calabrese et al. 1999), with more
NOAEL (no observed adverse effect level)
doses getting more points. This approach was
criticized by Crump (2001) on statistical
grounds. For example, it is important to
know the extent of statistical error and level of
signiﬁcance for NMDR relationships in sam-
pled literature. The next stage used combined
selection criteria for ad hoc entry and ad hoc
evaluation. This methodology produced 37%
of studies meeting evaluation criteria and, of
the 1,089 doses below the NOAEL, 213
(19.5%) satisﬁed statistical criteria (Calabrese
and Baldwin 2001b).
How well do the various screenings by
Davis and Svendsgaard (1994) or by
Calabrese and co-workers (Calabrese and
Baldwin 1997, 2001b; Calabrese et al. 1999)
reﬂect hormetic generalizability? At this time,
we do not know, as the approaches remain
unvalidated. Any ad hoc screening process for
a particular purpose requires validation for
reliable analysis and interpretation. One prob-
lem with the approach of Calabrese and
co-workers (Calabrese and Baldwin 2001b;
Calabrese et al. 1999) is dependence of fre-
quency estimation on entry criteria. Calabrese
and co-workers (Calabrese and Baldwin
2001b; Calabrese et al. 1999) require at least
two doses below the NOAEL. One can use an
equally or more reasonable criterion of three
or four doses, decreasing the frequency. 
Calabrese and Calabrese and Baldwin
reported illustrative possible, likely, or
observed bidirectional responses in various
endogenous and exogenous classes of sub-
stances or biological processes. Calabrese
claimed hormesis was present in studies of
estrogen and related compounds (2001f),
nitric oxide (2001h), prostaglandins (2001j),
chemotherapeutics (2005a), opiates (2001i),
adenosine (2001a), dopamine (2001e), sero-
tonin (2001g) androgens (2001b), apoptosis
(2001c), and cell migration/ chemotaxis
(2001d). Calabrese and Baldwin reported
hormesis for chemotherapeutics (2003a) and
such xenobiotic substances as ethanol
(2003b), peptides (2003e), diverse toxics
studied in the National Toxicology Program
for dose range (2003c), and metals (2003d).
The large survey of metals (Calabrese and
Baldwin 2003d) largely covers simple experi-
mental systems with few human data. 
Surveys of Calabrese and co-workers, as
cited in the previous paragraph, do not quan-
tify the global frequency of hormesis within
specific classes of substances. They merely
report instances of hormesis-type responses
across groups. For example, lead entails several
dozen or fewer citations over decades and for
limited experimental systems, a tally dwarfed
by the total number of lead citations, even
when taking account of study designs. In 1991
alone there were about 1,200 abstracted articles
listed in Chemical Abstracts (American
Chemical Society 1991) for human, experi-
mental and other laboratory studies, 600
abstracted articles on lead in experimental sys-
tems in Biological Abstracts (Union of
American Biological Societies 1991) and about
400 articles for both human and test animal
exposures in Index Medicus (National Library
of Medicine 1991; Mushak 1992).
What Is the Evidence for or
against Hormetic Phenomena
in Humans? 
A critical question for hormesis is its presence
and characterization in humans. A convincing
database in epidemiology, whatever the simple
experimental evaluations, is required to elevate
hormesis from scientiﬁc curiosity to something
providing possible ground truth for science
and health policy. A principal concern with
hormesis in humans is relevance to exposures
to large numbers of chemical contaminants,
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human populations by their nature are diverse
genetically and physiologically, making their
study for hormesis difﬁcult, especially for indi-
vidual members highly sensitive to toxicologic
or other biological challenge. Proponents of
hormesis readily point to moderate ethanol
consumption as producing beneﬁcial hormetic
behavior in humans (Calabrese and Baldwin
2003b). However, fetal ethanol exposures dur-
ing moderate maternal consumption during
pregnancy can produce neurotoxicologic fetal
injury such as abnormal neuronal migration
and abnormal development of the dendritic
spines, potentially producing mental retarda-
tion (Abel et al. 1983).
Radiologic hormesis. Some proponents of
radiologic hormesis hold that the linear no-
threshold (LNT) dose–response relationship
for radiologic carcinogenesis in humans and
experimental animals is no longer tenable and
radiologic hormesis should be the prevailing
model (e.g., Calabrese 2005b; Pollycove and
Feinendegen 2001). However, research into
radiologic carcinogenesis in humans continues
to feed a huge epidemiologic database docu-
menting the persistence of radiologic carcino-
genicity with lower dose. Little convincing
evidence exists to support human radiologic
hormetic responses nullifying the LNT model
of low-dose carcinogenesis. Current thinking
also is mixed about a conceptual context for
human radiologic hormesis (Johansson 2003;
Pollycove and Feinendegen 2001; Upton
2001).
Recent expert consensus treatises on low-
dose carcinogenicity of ionizing radiation in
humans present analyses largely supporting
the LNT model. The most recent report by
the NAS/NRC on the biological effects of ion-
izing radiation, BEIR VII-Phase 2 (NAS/NRC
2006), endorsed preservation of the LNT
model, that is, cancer risk proceeds in a linear
fashion at lower doses without a threshold.
Appendix D of the report covers radiation
hormesis. The report concluded that animal
and cell studies suggesting beneﬁts or thresh-
old to harm from ionizing radiation are “not
compelling” and that, at present, any assump-
tion of net health beneﬁts of radiation horme-
sis over detrimental impacts at the same dose
is unwarranted. 
The December 2004 draft report of the
International Commission on Radiation
Protection (ICRP 2004), the report of the
United Nations Scientiﬁc Committee on the
Effects of Atomic Radiation (2000), and the
report of the National Council on Radiation
Protection and Measurements (NCRP 2001)
have all concluded the LNT model remains
valid. The 2005 report of the joint French
National Academy of Medicine and the
Institute of France Academy of Sciences on
low dose-carcinogenic effect relationships for
ionizing radiation (Académie Nationale de
Médecine 2005) raises doubts about use of, or
recommendations for, the LNT model at low
(< 100 mSv) and very low (< 10 mSv) doses.
The French report refers to radiation hormesis
only in passing and in narrow context. 
Several recent epidemiologic studies are
consistent with an LNT dose response. The
Techa River study in the Southern Urals
region of Russia (Krestinina et al. 2005)
reported individualized risk estimates for excess
cancers from radioactivity exposures traced to a
weapons plant leak in the 1950s. The extended
cohort, with 29,873 people born between
1950 and 1960, provided strong evidence of
low-dose radiologic carcinogenesis. Cardis
et al. (2005), in their studies of 400,000
nuclear plant workers in 15 countries, con-
cluded that 1–2% of cancer deaths among the
cohort may be due to radiation. The results for
the nuclear workers produced conclusions sim-
ilar to those of the Techa River ﬁndings and
both articles support the ICRP standard of
20 mSv/year for occupational protection.
Chemical hormesis. I do not deny that
claimed chemical “hormesis” may exist in
some experimental data sets, whatever its
nature and overall frequency. However, clearly
demonstrable and interpretable hormetic
responses are not readily available from
human data. Rather, human data lend overall
support to conventional LNT or threshold
dose–response relationships. Two examples
are consistent with LNT dose response in
humans, low-level lead neurotoxicity in chil-
dren and low-dose arsenic cancer risks. 
Numerous reports document lead’s devel-
opmental neurotoxicity and other develop-
mental effects in children without threshold
[e.g., Centers for Disease Control and
Prevention (CDC) 2005; Lanphear et al.
2005; NAS/NRC 1993]. Developmental neu-
rotoxic effects detected in well-designed longi-
tudinal studies extend to blood lead (PbB)
levels well below 10 µg/dL (range, 3–7 µg/dL)
for children (Lanphear et al. 2005). The
authors’ pooled analysis of internationally
gathered longitudinal epidemiologic data actu-
ally shows the neurotoxic response relation-
ship at PbBs < 10 µg/dL as more robust than
for values > 10 µg/dL.
Inorganic arsenic (iAs) carcinogenicity con-
tinues to be documented in large epidemiologic
studies at lower and lower doses. Data sets for
low-dose iAs carcinogenicity include those from
Taiwan (e.g., Chen et al. 1992; Chiou et al.
2001; NAS/NRC 1999, 2001) and from South
American studies (e.g., Ferreccio et al. 2000;
Smith et al. 1998, 2006). Other data appeared
from Finland (Kurttio et al. 1999), China,
India, and Bangladesh [e.g., NAS/NRC (2001)
and references therein]. 
The NAS/NRC 1999 report concluded
there is no compelling reason for use of a
cancer risk model other than the LNT
approach. In fact, exposures producing mea-
surable iAs cancer rates approach earlier low-
dose extrapolation rates. Chiou et al. (2001)
found increased relative risks of 1.6 and 1.9
versus controls for urinary tract and transi-
tional cell cancers respectively with water As
intake of 10–50 ppb. 
Hormesis and human risk populations.
Little evidence exists that hormetic phenomena
play a role in either deﬁning human popula-
tions at elevated toxicity risk or in ameliorat-
ing or otherwise affecting heightened risk,
particularly with prenatal or early postnatal
exposures. Calabrese and Baldwin (2002b)
showed there is little evidence in the hormesis
literature linking hormesis to differential sensi-
tivity of human or other populations to vari-
ous toxic effects. Cook and Calabrese (2006)
erroneously used the Calabrese and Baldwin
(2002b) article to argue there is a hormetic
role in toxicologic sensitivities, but the earlier
article does not identify one.
Recent articles on hormesis largely fail to
address hormesis as a modifier of environ-
mental xenobiotic impacts on embryologic
and/or fetal development in humans or the
linkage of prenatal toxic exposures to postna-
tal developmental effects. There is a particu-
larly high risk for genetic or developmental
toxicologic harm in humans and experimental
animal systems exposed in utero. Noted above
was the ethanol example in pregnancy in
rebuttal to Calabrese and Baldwin (2003b).
Any putative role for hormesis is further
blurred by developments in two areas. First,
there is the ability of potent human carcino-
gens such as iAs and certain polycyclic aro-
matic hydrocarbons (PAHs) to function as
transplacental carcinogens in humans or ani-
mals. Second, there are endocrinologic toxic
responses, particularly those imparted
in utero, induced by endocrine disruptors. 
Drinking water iAs appears to be a trans-
placental carcinogen in humans and experi-
mental systems. Prenatal exposures produce
postnatal carcinogenic effects. Here, carcino-
genesis latency is also a developmental
latency. Arsenic crosses the human placental
barrier (Concha et al. 1998), whereas exten-
sive epidemiologic data associate arsenic expo-
sures with lung and hepatocellular carcinomas
(NAS/NRC 1999, 2001).
Data from a Chilean population exposed
to drinking water iAs show clear increased
mortality from lung cancer and bronchiectasis
in younger adults when exposures occurred
in utero and early childhood (Smith et al.
2006). Individuals born just before the peak
exposure period and exposed during early
childhood and those born during the high
exposure period with in utero and early child-
hood exposure all displayed significantly
increased standardized mortality ratios (SMRs)
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with the rest of Chileans 30–49 years of age.
Experimental ﬁndings in two different strains
of mice support this, showing iAs to be a com-
plete transplacental carcinogen in mice,
in utero exposures producing, for example,
hepatocellular carcinomas in the mice as adults
(Waalkes et al. 2003, 2004). Liu et al. (2006)
found the mouse toxicogenomic changes
in utero with iAs exposure to include oncogene
expression stimulation, liver feminization, cell
cycle dysregulation, and disruption of cell–cell
communication.
Certain PAHs appear to act as transpla-
cental developmental neurobehavioral toxi-
cants and carcinogens. Perera et al. (2006)
reported that highest quartile prenatal PAH
exposures in humans were linked to lower
Bayley scores at 3 years of age, whereas Yu
et al. (2006) showed that exposures of preg-
nant mice to dibenzo[a,l]pyrene produced
both increased mortalities in offspring at
12 weeks from an aggressive T-cell lym-
phoblastic lymphoma and lung tumors in all
animals surviving to 10 months, with some
having liver tumors. 
Endocrine disruptors have extremely high
toxicologic potency at extremely low doses,
especially in utero (e.g., Melnick et al. 2002;
Sheehan et al. 1999; Welshons et al. 2003).
How does hormesis deal with endocrine dis-
ruptors? The literature for endocrine disrup-
tors indicates that they may act without
threshold and even the LNT approach under-
states risk at extremely low doses. Disruptor
action involves saturation kinetics at receptor
sites, where early saturation and steep dose
responses are underestimated as to adverse
disruptor effects by even low-dose linear
extrapolations (Sheehan 2006; Sheehan et al.
1999; Welshons et al. 2003). 
Sheehan et al. (1999) found that there did
not appear to be a threshold dose for estradiol-
induced sex reversal of turtle embryos, the low-
est dose tested (40 pg/g, ppt) showing 14% sex
reversal in the turtle embryos. Sheehan (2006)
also analyzed 31 additional data sets. Use of a
normalized Michaelis-Menten equation for
data ﬁtting showed good ﬁt from about 1 to
> 95% receptor occupancy and contradicted
the threshold assumption. Welshons et al.
(2003) noted that exogenous estrogens partici-
pate in a physiologic system that is active and
already above any threshold due to endogenous
estrogens. They also noted linear low-dose
extrapolation, a typical risk assessment opera-
tion with substances such as carcinogens, may
be inappropriate and results in underestimated
risk above the physiologic zone where estrogen
activity is receptor mediated. Deviation of the
linearization line from the receptor occupancy
curve is evident in their Table 2.
Finally, hormesis discussions generally
ignore human genetic susceptibilities as a factor
in risk. Human toxicology data clearly show
the role of genetic variability in biotransforma-
tion of xenobiotics and one can consult any
works on pharmacogenetics for details. As one
example, genetic variability for iAs biotransfor-
mation (biomethylation) as a potential factor
in its carcinogenic potency has been docu-
mented (Chung et al. 2002; Vahter 2000; Yu
et al. 2003). 
Attempted Characterization of
the Hormetic Phenomenon’s
Underlying Mechanisms
Little in the way of actual de novo experimenta-
tion to speciﬁcally characterize the mechanistic
or biokinetic nature of hormesis has been car-
ried out. Mechanistic interpretations are often
speculative and descriptive, not data driven.
Calabrese and Baldwin (2002a) stated that
the mechanistic basis of the phenomenon is an
overcompensation induced by response to dis-
turbance of homeostasis. Any role for direct
stimulation has not been determined. Besides
a general mechanism of compensation, various
mechanisms were borrowed from literature
describing behaviors of certain substances. 
Adaptive, compensatory (overcompen-
satory) mechanisms in response to disturbed
homeostasis first require there be a time lag
during which the disturbance in homeostasis
occurs (Calabrese and Baldwin 2001c; Rozman
and Doull 2000). The time dependency is
expressed in a prehormetic low-dose region of
the dose–response curve for some end point
that is monotonic early in time, that is, is in
the opposite direction of the later hormetic or
“compensatory” segment of that curve (e.g.,
Calabrese and Baldwin 2001c). Does signiﬁ-
cant toxicity precede hormesis? Disturbances in
claimed homeostasis in any time period pre-
ceding onset of hormesis cannot be considered
pretoxicologic or toxicologically irrelevant. No
empiric or conceptual evidence for this exists.
If hormesis-linked homeostasis is a highly
evolved, efﬁcient process for organismal preser-
vation, it should logically respond sparingly if
at all to trivial, nontoxic challenges. Acceptance
of homeostasis preservation as the global mech-
anism for hormetic phenomena equally
requires acceptance of the occurrence of some
toxicologic event triggering hormesis. Second,
there is little evidence that any and all low-dose
toxicologic effects occurring prehormesis
(within the curve’s hormetic zone) would be
transitory over time and abate with onset of
hormesis, whatever the time-dependent curve
shape. There is evidence supporting the oppo-
site. Developmental neurotoxic metals produce
low-dose effects that are essentially irreversible. 
The observation of modest, relatively
invariant “hormetic” responses across various
end points and various classes of substances for
dose–response curves with a hormetic zone is
quite puzzling. Homeostatic preservation
would arguably predict compensatory (over-
compensatory) responses proportional to mag-
nitude of stressing events. However, the
hormetic response over “controls” is 30–60%
across many classes of substances and the
range of response is within one order of mag-
nitude or so. Why would highly efficient
preservation of somatic homeostasis exert as
much metabolic effort for responses to a
low-toxicity substance as for responses to a
high-toxicity substance? 
Conolly and Lutz (2004) have advanced
an alternative approach to hormetic mecha-
nisms. Nonmonotonicity seen in crude
graphic depictions of hormetic events is postu-
lated to be multiple effects with monotonic
dose–response curves superimposed on each
other, involving, for example, membrane
receptors with subtypes of varying ligand
affinities, androgen receptor-mediated gene
expression, repair of background DNA dam-
age by enzymatic activity induced by adducts,
and rates of mutation as a consequence of
DNA damage multiplied by rate of cell divi-
sion. Hormetic zones are rationalized as a net
expression of discrete and concurrent monoto-
nic molecular events. The Conolly and Lutz
scheme, however, does not appear to explain
the modest or invariant nature of hormetic
responses. Similarly, Kitchin and Drane
(2005) noted that multiple and different
mechanisms may attach to “beneﬁcial” versus
“toxic” effects, with aggregated impacts in
either direction contradicting any notion of a
single mechanism explanation.
What Are Limits to Borrowed
Mechanisms? 
It has not been established nor is it logical that
mechanisms proposed for claimed forms of
hormesis for different classes of substances—
drugs, essential nutrients, endogenous bioactive
substances—can be legitimately borrowed to
explain what is occurring mechanistically with
xenobiotics. Proponents of hormesis have nev-
ertheless borrowed liberally from their litera-
ture. Mechanisms of action of classes of drugs
are predetermined by purpose of the drug, the
systemic target(s) of the drug, and some phar-
macodynamic idea of therapeutic limits, and
not by treating the pharmacologic characteri-
zation of the drug as an antitoxicologic mecha-
nism. Mechanistic rationales for hormesis also
borrow from such areas as biotransformations
of xenobiotics, substance interactions deemed
potentially protective, and actions of essential
nutrients. 
The ability of xenobiotic organic com-
pounds to induce enzyme systems for their
metabolic biotransformation and detoxifica-
tion is not fully protective or compensatory to
the organism. Oxidative biotransformations
of PAHs produce readily excretable hydro-
philic conjugation products and protective
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adverse effect. The potent PAH carcinogen
benzo[a]pyrene (BaP) is metabolized to a
stereoisomeric mixture of diol epoxides. One
stereoisomeric form is held to be the proximate
carcinogen (e.g., Parkinson 2001). Such bio-
transformations typically occur with a latency
period and at relatively high dosing, rendering
any likely “protective” or “beneﬁcial” role with
low, sensitive toxic end points problematic. 
Biomethylation of iAs has been claimed to
be both a detoxiﬁcation mechanism and one
more complete at low doses (e.g., Buchet and
Lauwerys 1994). More recent studies support
biomethylation as a step in the substance’s
carcinogenic action (e.g., Mass et al. 2001).
In the area of many known multielement
interactions, the zinc (Zn)–cadmium (Cd)
interaction may appear hormetic, inducing
biosynthesis of metallothionein (MT) and
binding of Cd to yield the Cd–MT complex.
Although this complex is held to reduce Cd
binding and toxicity using certain toxicologic
end points, it can produce early nephrotoxic-
ity in the form of proximal tubular dysfunc-
tion [International Programme on Chemical
Safety (1992) and references therein]. 
The present placement of nutrients and
nutrient actions within conventional dose–
response frameworks from essentiality to toxi-
city allows some to deﬁne nutrient essentiality
as an example of hormesis. There are obvious
problems with this linkage.
Nutrients are biochemically and physio-
logically unlike xenobiotics or other exogenous
substances in not expressing toxic effects as an
intrinsic behavior central to their nutritive
role. Nutrients typically express such a high
therapeutic index (ratio of some deﬁned toxic
dose to some defined therapeutic dose) that
dual bioactivity is more accurately captured by
at least two separate dose–response curves.
Neither of these relationships convincingly
expresses a readily deﬁned hormetic response.
Nutrient “dose–response” relationships mainly
cover intakes producing nutrient deﬁciencies,
nutrient optimal activity, and preservation of
nutrient safety with excess intakes rather than
global, combined dose-responses that define
nutrient essentiality as a small early portion of
a mainly dose–toxicity curve. See Figures 2-4
to 2-6 of the World Health Organization text
(WHO 1996) for graphic depictions of mini-
mum, normative, and maximum population
zinc intakes defining the “dose” portions of
zinc’s nutritive dose responses.
Nutrients partake of a homeostasis
through control of uptake, distribution,
retention, deposition, or excretion (WHO
1996). Nutrient homeostasis should not be
considered equivalent to any homeostatic
mechanism for xenobiotic hormesis. Control
of nutrient biokinetics and essentiality works
more to prevent physiologically harmful
nutrient deficiencies and sustain optimal
nutrient utilization than it does to prevent
toxic effects of excessive nutrient intakes.
How Can Single End Point
Hormesis Accommodate
Multiple Toxic End Points,
Target Organs, and
Toxicologic Mechanisms?
The current hormesis literature is largely based
on isolated, single end points across a range of
doses. However, toxicants often operate to pro-
duce multisite toxicity via multiple end points
and likely multiple mechanisms, meaning data
are needed to determine which end point is the
most toxicologically sensitive. This end point
should then determine the dose–response
curve and hormetic phenomena therein.
There is also the matter of multiple effects
and their mechanisms producing erroneous
conclusions that hormesis is actually present
(Conolly and Lutz 2004; Kitchin and Drane
2005; Roberts 2001). Roberts (2001) made
general reference to low-dose multiple mecha-
nisms working in opposite directions creating
erroneous interpretations. Conolly and Lutz
(2004) provided concrete examples of the
potential for misinterpretation when multiple
low-dose processes are superimposed on each
other in the intact organism. An empirical
example is published data for Cd-induced sex
organ tumorigenesis in rats (Goyer et al. 2004;
Waalkes et al. 1988, 1997). The dose–response
curve for prostatic tumors in rats dosed with
Cd appears nonmonotonic at higher doses.
This response is not “hormetic” but expresses
tumorigenic interactions between prostatic and
testicular injury. Prostatic tumorigenic effects
in rats dosed with Cd occur at lower doses
than testicular tumors, whereas testicular injury
at higher doses occurs with altered androgen
release. Altered release changes the tumorigene-
sis dose–response curve for prostate tumor
rates at those higher doses. 
A statistical dimension to multiple end
point/multiple site relationships complicates
attributions to hormesis. Calabrese (2002) has
argued that organ-specific tumor induction
rates at three levels of dosings with 2,3,7,8-
tetrachlorodibenzo-p-dioxin in rats (Kociba
et al. 1978) is beneficial, in that aggregate
tumor rate is below the control rate. This is
misleading. Thayer et al. (2005) correctly
noted no reversal in tumor rates (curve direc-
tion) in any organ site for the doses used,
with only increases in tumors being recorded
in some sites versus controls. One cannot sta-
tistically dilute the data across tumor sites that
show higher rates over controls, i.e., are more
tumorigenically sensitive to dioxin exposures.
One also cannot dismiss elevated risk of
tumorigenesis for sensitive organ sites as the
driver for overall dioxin risk assessment. 
Does the Available Evidence
Support the Use of Hormesis
as a Default Assumption in
Human Risk Assessment and
Exposure Regulation Policies? 
The available evidence does not support the
use of hormesis for evaluating low-exposure
human health risk assessments and any imple-
menting of regulatory and health policy, espe-
cially for xenobiotic, potentially toxic
contaminants. Classes of drugs, essential nutri-
ents, or endogenous bioactive substances are
not the principal issue. The U.S. Food and
Drug Administration regulates drugs and the
NRC provides timely advisories on recom-
mended daily allowances for nutritional com-
ponents. We currently know little about the
temporal, mechanistic, genetic, or risk suscep-
tibility aspects of hormesis for use in any
human or ecologic risk assessment default
capacity. Using a default assumption requires
the assumption be a reliable and quantitatively
deﬁnable surrogate for speciﬁc but unavailable
data. Hormesis fails in this regard. 
Reasons for failure of hormesis in this
capacity are multiple. Frequency of hormesis in
nature or the literature shows it’s not univer-
sally present, being on the order of 20–25% or
less of examined examples (Calabrese and
Baldwin 2001b; Calabrese et al. 1999; Davis
and Svendsgaard 1994). This frequency in turn
cannot be ranked with other risk model
frequencies as some suggest (Calabrese and
Baldwin 2003f), since an independent, statisti-
cally acceptable global statistical sampling of all
published literature for all dose–response mod-
els has not been done. The above frequencies
are for experimental systems, with little con-
vincing evidence of hormesis in humans. 
Mechanistically, hormesis is a hypothesis
still in the realm of speculative assessment, rul-
ing out elevation to default assumption
(Conolly and Lutz 2004; Kitchin and Drane
2005; Thayer et al. 2005). It is not the case
that xenobiotics with a claimed hormetic zone
in their dose–response relationships show only
beneﬁcial behaviors or even show more beneﬁ-
cial than adverse effects at low dose (see above).
Proponents have uncoupled the idea of beneﬁt
or harm from their last effort at a definition
(Calabrese and Baldwin 2002a). This therefore
requires previous data before use. This analysis
and the work of others show that hormesis
does not accommodate human risk variability,
whatever the nature of that variability. Cook
and Calabrese (2006) erroneously assert
hormesis does accommodate risk variability. 
Hormesis does not accommodate multi-
ple toxic end points, target organs or mecha-
nisms. Use of single end points common in
hormesis would understate or misrepresent
the full toxicologic picture of low-dose effects
for reasons detailed earlier. Proponents argue
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for hormesis to be a beneficial effect would
promote human health. But how does one
use hormesis without knowing in advance
whether responses labeled hormetic are dele-
terious or beneficial? And how would one
know this in advance without first exposing
human populations? 
Is hormesis as default superior to other risk
models across the board? Class A chemical car-
cinogens and endocrine disruptors, two classes
of xenobiotics that figure or may figure in
many nonoccupational population exposure
scenarios, have not figured prominently in
attempted extension of hormesis to human
risk assessment. Second, available epidemio-
logic data offer little argument in favor of
hormesis as a preferred human risk model.
Hormesis proponents leave unsaid how the
factor of uncertainty is dealt with, in contrast
to the threshold risk models that employ
uncertainty factors. In fact, proponents have
not yet laid out a convincing methodologic
schematic that actually walks the reader or risk
assessor through a hormesis-based quantitative
risk assessment (Calabrese and Cook 2005). 
Conclusions
This review examined the phenomenon of
hormesis as currently defined and character-
ized. It was presented within a seven-topic
framework: deﬁnition, characterization, gener-
alizability, relevance to humans, mechanisms,
relevance to multiple toxic phenomena, and
role in risk assessment and regulatory or public
health policies.
One concludes:
• Deﬁnition, characterization, and generalizabil-
ity of hormesis remain largely problematic. 
• General mechanisms proposed for hormesis
appear driven more by speculation than by
empirical evidence from speciﬁc mechanistic
testings, while similarities to other phenom-
ena do not permit mechanistic borrowing.
• It is unlikely that single end point hormesis
would be quantitatively useful for toxics
expressing multiple toxic effects in multiple
organs and through multiple mechanisms. 
• Until hormesis is rigorously studied through
new and specifically designed protocols
for hypothesis testing, its nature remains
speculative.
• Persisting, serious limits to all the above
aspects of hormesis hobble and likely will
continue to hobble its use for regulatory and
public health policies.
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